SMART-ToC is conducted by a transdisciplinary team set to develop an advanced breast tumor-on-chip model as a tool to test novel anti-cancer therapies and enable personalized medicine.
4 years | 4 countries | 6 societal & industry partners & 4 research institutions (2 technical universities, 1 applied science university & 1 university medical centre)
Tumor tissues are highly heterogeneous and vary with disease progression. Heterogeneity, as reported for certain microenvironmental parameters (oxygen, pH, tissue stiffness), often correlates with poor treatment success. Yet, current in-vitro/in-vivo tumor models do not properly incorporate spatiotemporal variations and thus have limited translational value. Therefore, innovative approaches are needed for advanced modeling of the tumor microenvironment, that correlate spatiotemporal alterations to therapy responses, to ultimately understand interrelationships and facilitate cost-effective (immuno)therapy development. Such approaches will be a gamechanger towards in vitro pharmacokinetics studies and provide a trajectory towards personalized medicine, after model personalization using patient-derived materials.
SMART-ToC will develop an advanced breast tumor-on-chip model incorporating essential cellular, physical, and chemical elements that impact therapeutic response; validate this model for antibody-drug conjugates and immunotherapies; and conduct an innovation trajectory towards societal acceptance. The proposed breast tumor-on-chip comprises a 3D-multicellular culture of breast tumor, innate immune cells, cancer- associated fibroblasts, and a vasculature, in a tunable (animal-free) hydrogel matrix equipped with sensors to map in 3D important microenvironmental parameters (pH, oxygen and stiffness). The model will be applied to evaluate therapeutic efficacy for antibody- and virus-based immunotherapies, in comparison to healthy breast tissue for tolerability studies.

Working packages (WP)
WP1 | SMART hydrogels with tunable properties and sensing capabilities.
The aim of this WP is to develop SMART (Sensing hydrogel MAtrices correlating microenvironment and Response to immunoTherapy) hydrogels to incorporate in the breast cancer on chip platform. These matrices will possess fine-tunable properties (e.g., mechanical strength, cell-adhesion, degradability rate) and incorporate various sensors to map in real-time pH, oxygen tension, and mechanical forces in 3D.
WP2 | SMART tumor-on-chip model.
The aims of this WP are to develop the vascularized SMART-tumor on chip (ToC) model comprising a triple co-culture of breast cancer cells, cancer associated fibroblasts (CAFs), and immune cells (healthy tissue being a reference) in the SMART sensing matrices from WP1, to validate it with small chemotherapeutic agents, and to upgrade it for future large-scale production.
WP3 | Model validation for therapeutic applications.
The purpose of WP3 is to validate the SMART-ToC model from WP2 for its versatile use in therapy development. Specifically, we will demonstrate its utility for gaining insights into tolerability, therapeutic efficacy, and pharmacokinetics, for two approaches, antibody-drug conjugates (ADCs), and viral immunotherapies.
WP4 | Societal and ethical parallel trajectory.
In this WP, we will assess the societal and ethical readiness of SMART-ToC by applying a societal and ethical parallel trajectory (SEPT) with multiple interventions throughout the project. These activities aim to stimulate continuous reflection, create insights relevant for the design and development process of SMART-ToC, offer perspectives for future use and alternative applications, and inspire a culture of responsible and sustainable research and innovation
WP5 | Knowledge utilization.
The aims of this WP are to disseminate and communicate the project outcomes to a broad variety of audiences; to develop educational activities related to OoCs to train the new generation of scientists and to exploit SMART-ToC innovative technologies for future commercialization, by engaging with relevant stakeholders and end-users.
About the partners
Scientific partners
UTwente | Le Gac’s lab: Applied Microfluidics for Bioengineering Research (AMBER)
Séverine Le Gac is chairing the Applied Microfluidics for Bioengineering Research group at the UT and has over 20 years’ experience in microfluidics and organ-on-chip technologies. She develops, with her team, innovative miniaturized devices for cancer research and reproductive medicine, and to evaluate the impact of plastics on human health. She has ample experience with industrial collaborations (e.g., OTP-NWO, TKI-LSH Health-Holland, Merck Serono, Hitachi), and technology transfer. She is the consortium coordinator and the main responsible for WP2. Within SMART-ToC, her team will develop the microfluidic platform, optimize cell patterning to create a vascularized tumor model, and conduct first-stage drug testing using chemotherapeutics.
Ali Al-Jaberi (PhD candidate) is a biomedical engineer with a background in Biotechnology for Health and Health Engineering from the University of Grenoble Alpes. During his Master's thesis, he participated in developing a vascularized renal proximal tubule-on-a-chip platform. His role in SMART-ToC is to develop a vascularized breast tumor model comprising a triple co-culture of breast cancer cells, cancer-associated fibroblasts (CAFs), and immune cells in tunable sensing matrices, and to validate the model for chemotherapy and immunotherapy applications.
Link to AMBER Research group webpage
UTwente | Paez lab
Julieta Paez is Associate Professor at the Developmental Bioengineering Group of the BioEngineering Technologies department at the UT and has expertise in synthetic macromolecular and biomaterials chemistry as well as soft matter applied to biomedicine. She started her independent career in 2019 as a Project Leader at INM—Leibniz Institute for New Materials in Germany and then joined the UT in 2021 as a tenure tracker. She has experience in collaborative projects with industry and in transfer of technology. She is the consortium co-coordinator and the main responsible for WP1. Within SMART-ToC, her team will develop the sensing hydrogel matrix with modulable properties to embed the tumor cells.
Minye Jin is a material scientist with a background in polymer science. Within SMART-ToC, she developed soft matrices as 3D cell culture scaffolds for breast tumor model to validate its use for chemotherapy and immunotherapy applications. By varying the crosslinking chemistry and formulations, the resulting soft matrices exhibited tunable mechanical properties with sensing capabilities.
UniFri | Ruggi Group
Albert Ruggi is Senior Lecturer (Maître d'Enseignement et de Recherche) at the University of Fribourg (CH). He has extensive experience in photochemistry, including the design, synthesis, and photochemical evaluation of different classes of organic and inorganic compounds. He brings his expertise to WP1, developing the molecular sensors for oxygen and pH monitoring to functionalize the hydrogel matrices where the tumor will be embedded.
Greta Sandri (PhD candidate) She graduated with a Master's degree in Organic Chemistry from Sapienza University of Rome, Italy. She is currently conducting her research at the University of Fribourg, Switzerland, in Dr. Albert Ruggi's laboratory. Within the SMART-ToC project, her role is to synthesize oxygen- and pH-sensitive probes for integration into sensing matrices, contributing to the development of responsive platforms for monitoring the tumor microenvironment.
RadboudUMC | Verdurmen Lab
Wouter Verdurmen obtained his PhD cum laude at the Dept. of Biochemistry and is currently an Assistant Professor at the Dept. of Medical BioSciences, both at Radboudumc. After receiving a Rubicon grant (2012) to support his postdoctoral stay at the University of Zurich (CH), he received a prestigious Veni grant in 2015. Since 2016, with his group, he has been studying the efficacy of novel therapies and drug delivery mechanisms and kinetics in various models including (immunocompetent) OoC systems. His group’s work focusses on engineered antibodies and adenoviral therapies in application areas involving cancer, endometriosis, and fibrosis. He is the main responsible for WP2. Within SMART-ToC, his team will test novel immunotherapies and validate the SMART-ToC device as screening device.
Nadine Gimenez is a biomedical scientist with a background in cancer biology and immunotherapy. During her PhD, she used 2D cell cultures and a tumor-on-chip model to investigate the potential of a gene therapy to induce immunogenic cell death in prostate cancer. Her role in SMART-ToC is to use the breast tumor-on-chip platform to evaluate antibody–drug conjugates and viral immunotherapies, focusing on their toxicity and capacity to engage the immune system.
Saxion | Ethics & Technology group
Steven Dorrestijn chairs the group Ethics & Technology at Saxion University of Applied Sciences. His research focusses on the impact and ethics of technology. He develops practical methods & tools to stimulate reflection about technology, like the product impact tool and Ethical Readiness Check. In his approach of an Ethical Parallel Track, these tools and others are applied implementation of responsible innovation in an integral way. He has been president of the board of the Dutch Association of Philosophy & Healthcare (VFG). Within SMART-ToC he is the supervisor of the activities and methods executed in WP4 (Societal and ethical parallel trajectory).
Verena Schulze Greiving is a senior researcher, project leader, and lecturer in the research group Ethics & Technology at Saxion University of Applied Sciences (Netherlands). After a MSc & PhD in Nanotechnology, she gained experience as a PostDoc in Responsible Research & Innovation, Science & Technology Studies, and Constructive Technology Assessment at the University of Twente. In her current work, she focusses on the development and implementation of practical methods to stimulate ethical and societal reflection in research and education. As a leader of WP4, Dr. Schulze Greiving is coordinating the assessment of the ethical, legal and social aspects (ELSA) related to the tumor platform developed in SMART-ToC, the organization of ethical interventions and workshops with researchers and external stakeholders, and the integration of ethics in (engineering) education.
Jan Kaptijn is a researcher in Ethics and Technology at Saxion University of Applied Sciences. He has a background in philosophy and computer science. Within SMART-ToC, he focuses on the social environment in which research and innovation take place, especially on the impact of the research done in SMART-ToC on the use of animal experiments.
Link to Ethics & Technology group
Saxion | Applied Nanotechnology group
Martin Bennink is Professor of Applied Nanotechnology at Saxion University of Applied Sciences and leads an interdisciplinary research group of approximately 40 researchers. His activities include applied interdisciplinary research on lab-on-a-chip and organ-on-a-chip technologies, bio-inspired materials, and the development of highly sensitive molecular sensing technologies for applications in the medical and forensic domains. Projects encompass not only technological development but also the implementation of these technologies in real-world practice.
Aniek Welman is a researcher at the Research Group Applied Nanotechnology at Saxion University of Applied Sciences. Within the SMART-ToC project, she collaborates with colleagues from the Research Group Ethics & Technology to identify and explore the societal and ethical challenges associated with the development and application of SMART-ToC technology.
Industrial partners
Fluigent is an international company offering cutting-edge microfluidic solutions to enhance fluid control in research and industrial settings. Our products include precision pressure controllers, flow rate sensors, and systems designed for complex fluid handling processes. With a focus on accuracy and reliability, our patented pressure controllers serve thousands of laboratories and support applications across life sciences, chemistry, engineering, and physics. Link to Fluigent website.
ibidi is a leading supplier of functional cell-based assays and advanced products for cellular microscopy. Headquartered in Germany, ibidi supports researchers worldwide with innovative solutions that are featured in more than 10 peer-reviewed publications every day and referenced in over 5,000 patents. Link to ibidi website
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Healthcare areas include: Oncology, Immunology, Neuroscience and Cardiopulmonary.
Societal partners
Proefdiervrij is a Dutch foundation committed to making the use of laboratory animals superfluous in scientific research. They focus on the prevention and replacement of laboratory animals in scientific research. Link to Proefdiervrij website
hDMT is the Institute for Human organ and Disease Model Technologies, comprising 16 partners including (technical) universities, university medical centers and knowledge institutes. Their mission is to facilitate and support the development of dynamic human models and their translation into practical applications for research, innovation, and a healthier future. Link to hDMT website
TNO is an independent research organization in the Netherlands that drives innovation by connecting science with practical applications. Link to TNO website
Support
Ana Ortiz-Perez, current project manager.
Elena Refet-Mollof, former project manager.
Outreach
Do you want to know more about the importance of tumor microenvironment and tumor on chip technologies? Check this interactive website: https://toc-tme-amber.netlify.app/.
Funding
This project with file number KICH1.ST04.22.015 of the research programme KIC - MISSION Emerging Key Enabling Technologies is financed by the Dutch Research Council (NWO).
Organisations
Annual Meeting 2026
On November 10, the SMART-ToC consortium held its annual scientific and users’ committee meeting at Saxion University of Applied Sciences in Deventer, the Netherlands.
The entire consortium and scientific advisory board, with a variety of scientific, industrial, and societal partners came together to share updates on project progress, exchange insights, and discuss future directions. The meeting provided a valuable opportunity to strengthen collaboration across the consortium and align on the next steps towards achieving the project's objectives and to reflect, in the context of a dynamic workshop, on everybody’s expectations and possible outcomes for the SMART-ToC project.
A big thank you to all partners/participants for their contributions and all engaging/enthusiastic discussions. We look forward to another year of fruitful collaborations!

Conference talk: TERMIS 2026
During the the TERMIS-EU 2026 Conference in Palma de Mallorca (Spain), our scientist Dr. Minye Jin presented her work on "Advancing collagen I-based tumor-on-chip models: from tunable mechanics to 3D mechanical sensing capability"
Read more: TERMIS 2026
Conference talk: NWO CHAINS 2025
During NWO CHAINS 2025 (the Dutch Chemistry conference) in Veldhoven, our scientist Dr Minye Jin presented her work on "Novel photochemical strategy to fabricate tunable and sensing collagen hydrogels for tumor-on-chip-modelling".

Read more in: NWO CHAINS 2025 The chemistry of bonding
Conference talk: NBTE 2025
During the Netherlands Society for Biomaterials and tissue engineering (NBTE) 2025, in Lunteren, our scientist Dr. Minye Jin presented her work entitled "Development of Mechanically tunable and sensing collagen hydrogels for tumor on chip modelling".
Read more: NBTE 2025










